mRNA Vaccine for Skin Cancer: Moderna and Merck Announce Historic Phase III Trial Success
On August 19, Moderna and Merck announced the successful completion of Phase III of an mRNA vaccine against melanoma: a combined regimen with a 49% reduction in recurrence risk paves the way for licensing personalized cancer therapy.
Read more →